This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arpin, C.
Right arrow Articles by Quentin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arpin, C.
Right arrow Articles by Quentin, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1999, p. 944-946, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Presence of mefA and mefE Genes in Streptococcus agalactiae

C. Arpin,* H. Daube, F. Tessier, and C. Quentin

Laboratoire de Microbiologie, Université Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France

Received 9 November 1998/Returned for modification 9 December 1998/Accepted 14 January 1999


    ABSTRACT
Top
Abstract
Text
References

Eighteen unrelated clinical isolates of Streptococcus agalactiae with the M phenotype harbored an mef gene. DNA sequencing showed that one of nine strains contained mefA (producing one amino acid substitution), whereas the remaining eight carried mefE (identity, 100%). Restriction analysis of PCR products indicated that the nine other strains also contained mefE.


    TEXT
Top
Abstract
Text
References

Streptococcus agalactiae (group B streptococcus) is mainly responsible for meningitis and septicemia in newborns; beta-lactam agents are the treatment of choice of these infections, but macrolides and related drugs are useful alternate therapy in allergic patients (2, 13). Until recently, the only known mechanism of resistance to macrolides in streptococci was target site modification by 23S rRNA methylases, encoded by the erm genes. The Erm enzymes convey cross-resistance to macrolides, lincosamides, and the streptogramin B compounds (MLS), which is referred to as MLSB phenotype (23). Since the late 1980s, a new phenotype, designated M and consisting of resistance to 14- and 15-membered macrolides but susceptibility to 16-membered macrolides, lincosamides, and streptogramins, has been recognized in group A streptococci and pneumococci isolated in a number of countries (6, 8, 9, 15-17, 19, 21, 24, 25). The mechanism of this resistance is a proton-dependent efflux system (4, 11, 21, 22), encoded by mef genes: mefA in group A streptococci (4) and mefE in pneumococci (22), which have 90% identity. mef genes have also been detected very recently in group C streptococci (10). Preliminary studies indicated that they might be widespread among other streptococcal species, including S. agalactiae (22). In addition, a novel efflux system, encoded by mreA, distinct from the Mef pump, has been characterized in a single strain of S. agalactiae which displayed resistance to 14-, 15-, and 16-membered macrolides (5). The aim of the present study was to determine the macrolide resistance mechanism in 18 clinical strains of S. agalactiae bearing the M phenotype.

These 18 nonredundant isolates (SB1 to SB18) were collected from distinct patients in several laboratories in the southwest of France, from 1993 to 1998. They were mainly recovered from genital samples of adults and gastric fluid of neonates. Three clinical strains of S. agalactiae, susceptible or expressing inducible or constitutive MLSB phenotypes, were also used as controls. Identification was done by conventional tests (13). MICs of 12 MLS drugs were determined by an agar dilution method in Mueller-Hinton medium supplemented with 5% horse blood, with a final inoculum of 105 CFU per spot (7). The strains showed low-level resistance to 14- and 15-membered macrolides while being fully susceptible to 16-membered macrolides, lincosamides, and pristinamycin II (group A) and pristinamycin I (group B), even after prolonged incubation at 37°C in aerobiosis (Table 1). MICs were slightly lower than those obtained for the strains of group A streptococci (8, 15, 17, 25) or pneumococci (9, 18) with an M phenotype (MICs of erythromycin at 4 to 8 mg/liter). Moreover, subinhibitory concentrations of erythromycin (0.005 to 8 µg/ml) or lincomycin (0.0002 to 0.5 µg/ml) did not induce MLS resistance in the first nine erythomycin-resistant strains of S. agalactiae that we tested (SB1 to SB9). Finally, the possibility that an erm gene was present was excluded by two experiments: dot blot DNA hybridization under conditions of low and high stringencies performed by using radioactively labelled ermAM probe, and amplification by PCR by using degenerate oligonucleotides corresponding to conserved amino acid motifs in Erm methylases (1).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Susceptibility of S. agalactiae clinical strains to MLS antibiotics

Then, DNA amplification by PCR was performed with genomic DNA of the 18 isolates, using primers specific for the mef genes, i.e., mef1 (5'-ATGGAAAATACAACAATTGGAAAC-3'; 5'-ATG translation start codon is underlined) and mef8 (5'-TTATTTAAATCTAATTTTCTAACCTC-3'; TAA-3' translation stop codon is underlined). Amplification products of 1.2 kb were obtained in all cases, in contrast with negative controls (DNA of a susceptible strain or strains with an MLSB phenotype). The presence of an erythromycin resistance gene was further characterized in half of the strains (SB1 to SB9). Mating between the nine isolates and a streptomycin-resistant mutant of S. agalactiae BM132 as the recipient strain was carried out on filters (7). No transfer was observed, in contrast to the positive control (S. agalactiae BM132 harboring an ermAM gene on a conjugative plasmid; transfer frequency, 10-5). Furthermore, plasmid DNA was not detected after extraction and analysis by electrophoresis on agarose gel (14). Erythromycin resistance in Streptococcus pyogenes was found in one case to be transferable by conjugation to streptococci or Enterococcus faecalis recipients, although no plasmid DNA could be detected (15). However, no information has been provided on the transferability of mef genes (22).

For the same nine strains, the PCR products were directly sequenced on both strands by an automated fluorescent sequencing method. The analysis showed that one of these amplimers (pSB1) was identical to mefA (4), except for two substitutions: one silent mutation at position 471 (Tright-arrowC) and one mutation at position 239 (Aright-arrowC) that led to the replacement of a methionine by a valine at position 77. This is the first description of the mefA gene in S. agalactiae. Hybridization experiments, using this amplified product (pSB1) radioactively labelled and used as a probe, gave a weaker signal with the eight remaining amplified products (pBS2 to pBS9) than with the positive control (pBS1). Indeed, all nucleotide sequences of pBS2 to pBS9 exhibited 100% identity with the original mefE gene (GenBank accession no. U83667) (22). There was no apparent clustering of our strains. However, as a confirmation, epidemiological typing by randomly amplified polymorphic DNA was performed, since this method has been found to be discriminant for this species (3). Using primer AP12h (5'-CGGCCCCTGT-3'; 80% G+C content) and the method described elsewhere (3), the SB1 to SB9 strains of S. agalactiae were found to exhibit different patterns and thus were concluded to be multiclonal isolates.

Finally, the PCR products obtained with the nine other strains (SB10 to SB18) were analyzed after restriction by four endonucleases (AccI, ClaI, HindIII, and HhaI) designed to digest differentially mefA and mefE. The nine amplimers gave restriction patterns consistent with mefE rather than with mefA. These findings confirmed the predominance of mefE among S. agalactiae strains with an M phenotype. The distribution of the mef genes has been studied only in pneumococci, where mefE was exclusively found (18). Enzymatic restriction combined with PCR amplification should be helpful to determine the relative prevalence of the mef genes among various streptococcal species.

In the late 1980s, a sudden increase in the frequency of erythromycin-resistant streptococci was observed in several countries (including the United Kingdom, Finland, and the United States) (6, 15, 16, 19, 25), and this was probably related to the increased prescription of this antibiotic or its then newly available semisynthetic derivatives (16). In these countries, the prevalence of the M phenotype (and/or mef genes) among the erythromycin-resistant streptococci is very high: 38 to 97% in group A streptococci (8, 17, 20), 95% in group C streptococci (10), and 41 to 85% in pneumococci (9, 18, 20). In France, no national data are available. In our area, between 1996 and 1997, the percentages of erythromycin-resistant strains at different hospitals ranged from 31 to 56% for pneumococci, from 0 to 20% for group A and group C streptococci, and from 8 to 16% for group B and group G streptococci (12). MLSB phenotype remains widely predominant since only two strains of group A streptococci, one strain of group C streptococci, and one strain of S. pneumoniae containing an mef gene (data not shown) have been collected, compared to 18 isolates of S. agalactiae that were collected during the same period. Our findings emphasize the need to perform cultures and susceptibility testing whenever streptococcal infections are suspected; antibiograms should include 16-membered macrolides or lincosamides, since these drugs may remain active against erythromycin-resistant streptococci.


    ACKNOWLEDGMENTS

We thank P. Courvalin for useful advice. We are indebted to M. H. Canron and C. André for expert technical assistance.


    FOOTNOTES

* Corresponding author. Mailing address: Laboratoire de Microbiologie, Université Victor Segalen Bordeaux 2, 146, rue Léo Saignat, 33076 Bordeaux Cedex, France. Phone: (33) 5-57-57-10-75. Fax: (33) 5-56-90-90-72. E-mail: corinne.arpin{at}bacterio.u-bordeaux2.fr.


    REFERENCES
Top
Abstract
Text
References

1. Arthur, M., C. Molinas, C. Mabilat, and P. Courvalin. 1990. Detection of erythromycin resistance by the polymerase chain reaction using primers in conserved regions of erm rRNA methylase genes. Antimicrob. Agents Chemother. 34:2024-2026[Abstract/Free Full Text].
2. Backer, C. J. 1997. Group B streptococcal infections. Clin. Perinatol. 24:59-70[Medline].
3. Chatellier, S., C. Ramanantsoa, P. Harriau, K. Rolland, A. Rosenau, and R. Quentin. 1997. Characterization of Streptococcus agalactiae strains by randomly amplified polymorphic DNA analysis. J. Clin. Microbiol. 35:2573-2579[Abstract].
4. Clancy, J., J. Petitpas, F. Dib-Hajj, W. Yuan, M. Cronan, A. V. Kamath, J. Bergeron, and J. A. Retsema. 1996. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol. Microbiol. 22:867-879[Medline].
5. Clancy, J., F. Dib-Hajj, J. W. Petitpas, and W. Yuan. 1997. Cloning and characterization of a novel macrolide efflux gene, mreA, from Streptococcus agalactiae. Antimicrob. Agents Chemother. 41:2719-2723[Abstract].
6. Coonan, K. M., and E. L. Kaplan. 1994. In vitro susceptibility of recent North American Group A streptococcal isolates to eleven oral antibiotics. Pediatr. Infect. Dis. J. 13:630-635[Medline].
7. Courvalin, P., F. Goldstein, A. Philippon, and J. Sirot (ed.). 1985. L'antibiogramme. MPC-VIDEOM, Brussels, Belgium.
8. Garcia-Bermejo, I., J. Cacho, B. Orden, J.-I. Alós, and J.-L. Gómez-Garcés. 1998. Emergence of erythromycin-resistant, clindamycin-susceptible Streptococcus pyogenes isolates in Madrid, Spain. Antimicrob. Agents Chemother. 42:989-990[Free Full Text].
9. Johnston, N. J., J. C. de Azavedo, J. D. Kellner, and D. E. Low. 1998. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin in isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2425-2426[Abstract/Free Full Text].
10. Kataja, J., H. Seppälä, M. Skurnik, H. Sarkkinen, and P. Huovinen. 1998. Different erythromycin resistance mechanisms in group C and group G streptococci. Antimicrob. Agents Chemother. 42:1493-1494[Abstract/Free Full Text].
11. Paulsen, I. T., M. H. Brown, and R. A. Skurray. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60:575-608[Abstract/Free Full Text].
12. Quentin, C. Personal communication.
13. Ruoff, K. L. 1995. Streptococcus, p. 299-307. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
14. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
15. Scott, R. J. D., J. Naidoo, N. F. Lightfoot, and R. C. George. 1989. A community outbreak of Group A beta haemolytic streptococci with transferable resistance to erythromycin. Epidemiol. Infect. 102:85-91[Medline].
16. Seppälä, H., A. Nissinen, H. Järvinen, S. Huovinen, T. Henriksson, E. Herva, S. E. Holm, M. Jahkola, M.-L. Katila, T. Klaukka, S. Kontiainen, O. Liimatainen, S. Oinonen, L. Passi-Metsomaa, and P. Huovinen. 1992. Resistance to erythromycin in Group A streptococci. N. Engl. J. Med. 326:292-297[Abstract].
17. Seppälä, H., A. Nissinen, Q. Yu, and P. Huovinen. 1993. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J. Antimicrob. Chemother. 32:885-891[Free Full Text].
18. Shortridge, V. D., R. K. Flamm, N. Ramer, J. Beyer, and S. K. Tanaka. 1996. Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 26:73-78[Medline].
19. Stingemore, N., G. R. J. Francis, M. Toohey, and D. B. McGechie. 1989. The emergence of erythromycin resistance in Streptococcus pyogenes in Fremantle, Western Australia. Med. J. Aust. 150:626-631[Medline].
20. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566[Abstract].
21. Sutcliffe, J., A. Tait-Kamradt, and L. Wondrack. 1996. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob. Agents Chemother. 40:1817-1824[Abstract].
22. Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, and J. Sutcliffe. 1997. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:2251-2255[Abstract].
23. Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577-585[Medline].
24. Wu, J.-J., K.-Y. Lin, P.-R. Hsueh, J.-W. Liu, H.-I. Pan, and S.-M. Sheu. 1997. High incidence of erythromycin-resistant streptococci in Taiwan. Antimicrob. Agents Chemother. 41:844-846[Abstract].
25. Youngs, E. R. 1984. Erythromycin resistant Streptococcus pyogenes in Merseyside. J. Infect. 8:86-87[Medline].

Antimicrobial Agents and Chemotherapy, April 1999, p. 944-946, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Cai, Y., Kong, F., Gilbert, G. L. (2007). Three New Macrolide Efflux (mef) Gene Variants in Streptococcus agalactiae. J. Clin. Microbiol. 45: 2754-2755 [Full Text]  
  • Puopolo, K. M., Klinzing, D. C., Lin, M. P., Yesucevitz, D. L., Cieslewicz, M. J. (2007). A composite transposon associated with erythromycin and clindamycin resistance in group B Streptococcus. J Med Microbiol 56: 947-955 [Abstract] [Full Text]  
  • Gygax, S. E., Schuyler, J. A., Kimmel, L. E., Trama, J. P., Mordechai, E., Adelson, M. E. (2006). Erythromycin and clindamycin resistance in group B streptococcal clinical isolates.. Antimicrob. Agents Chemother. 50: 1875-1877 [Abstract] [Full Text]  
  • Amezaga, M. R., McKenzie, H. (2006). Molecular epidemiology of macrolide resistance in {beta}-haemolytic streptococci of Lancefield groups A, B, C and G and evidence for a new mef element in group G streptococci that carries allelic variants of mef and msr(D). J Antimicrob Chemother 57: 443-449 [Abstract] [Full Text]  
  • Zeng, X., Kong, F., Wang, H., Darbar, A., Gilbert, G. L. (2006). Simultaneous Detection of Nine Antibiotic Resistance-Related Genes in Streptococcus agalactiae Using Multiplex PCR and Reverse Line Blot Hybridization Assay. Antimicrob. Agents Chemother. 50: 204-209 [Abstract] [Full Text]  
  • Marimon, J. M., Valiente, A., Ercibengoa, M., Garcia-Arenzana, J. M., Perez-Trallero, E. (2005). Erythromycin Resistance and Genetic Elements Carrying Macrolide Efflux Genes in Streptococcus agalactiae. Antimicrob. Agents Chemother. 49: 5069-5074 [Abstract] [Full Text]  
  • Klaassen, C. H. W., Mouton, J. W. (2005). Molecular Detection of the Macrolide Efflux Gene: To Discriminate or Not To Discriminate between mef(A) and mef(E). Antimicrob. Agents Chemother. 49: 1271-1278 [Full Text]  
  • Wierzbowski, A. K., Swedlo, D., Boyd, D., Mulvey, M., Nichol, K. A., Hoban, D. J., Zhanel, G. G. (2005). Molecular Epidemiology and Prevalence of Macrolide Efflux Genes mef(A) and mef(E) in Streptococcus pneumoniae Obtained in Canada from 1997 to 2002. Antimicrob. Agents Chemother. 49: 1257-1261 [Abstract] [Full Text]  
  • Heelan, J. S., Hasenbein, M. E., McAdam, A. J. (2004). Resistance of Group B Streptococcus to Selected Antibiotics, Including Erythromycin and Clindamycin. J. Clin. Microbiol. 42: 1263-1264 [Abstract] [Full Text]  
  • Bingen, E., Doit, C., Bidet, P., Brahimi, N., Deforche, D. (2004). Telithromycin Susceptibility and Genomic Diversity of Macrolide-Resistant Serotype III Group B Streptococci Isolated in Perinatal Infections. Antimicrob. Agents Chemother. 48: 677-680 [Abstract] [Full Text]  
  • Lopardo, H. A., Vidal, P., Jeric, P., Centron, D., Paganini, H., Facklam, R. R., Elliott, J. (2003). Six-Month Multicenter Study on Invasive Infections Due to Group B Streptococci in Argentina. J. Clin. Microbiol. 41: 4688-4694 [Abstract] [Full Text]  
  • Montanari, M. P., Mingoia, M., Cochetti, I., Varaldo, P. E. (2003). Phenotypes and Genotypes of Erythromycin-Resistant Pneumococci in Italy. J. Clin. Microbiol. 41: 428-431 [Abstract] [Full Text]  
  • Culebras, E., Rodriguez-Avial, I., Betriu, C., Redondo, M., Picazo, J. J. (2002). Macrolide and Tetracycline Resistance and Molecular Relationships of Clinical Strains of Streptococcus agalactiae. Antimicrob. Agents Chemother. 46: 1574-1576 [Abstract] [Full Text]  
  • Pihlajamaki, M., Kataja, J., Seppala, H., Elliot, J., Leinonen, M., Huovinen, P., Jalava, J. (2002). Ribosomal Mutations in Streptococcus pneumoniae Clinical Isolates. Antimicrob. Agents Chemother. 46: 654-658 [Abstract] [Full Text]  
  • Lim, J.-A., Kwon, A.-R., Kim, S.-K., Chong, Y., Lee, K., Choi, E.-C. (2002). Prevalence of resistance to macrolide, lincosamide and streptogramin antibiotics in Gram-positive cocci isolated in a Korean hospital. J Antimicrob Chemother 49: 489-495 [Abstract] [Full Text]  
  • Teng, L.-J., Hsueh, P.-R., Ho, S.-W., Luh, K.-T. (2001). High Prevalence of Inducible Erythromycin Resistance among Streptococcus bovis Isolates in Taiwan. Antimicrob. Agents Chemother. 45: 3362-3365 [Abstract] [Full Text]  
  • De Mouy, D., Cavallo, J.-D., Leclercq, R., Fabre, R., The Aforcopi-Bio Network, (2001). Antibiotic Susceptibility and Mechanisms of Erythromycin Resistance in Clinical Isolates of Streptococcus agalactiae: French Multicenter Study. Antimicrob. Agents Chemother. 45: 2400-2402 [Abstract] [Full Text]  
  • Fitoussi, F., Loukil, C., Gros, I., Clermont, O., Mariani, P., Bonacorsi, S., Le Thomas, I., Deforche, D., Bingen, E. (2001). Mechanisms of Macrolide Resistance in Clinical Group B Streptococci Isolated in France. Antimicrob. Agents Chemother. 45: 1889-1891 [Abstract] [Full Text]  
  • Santagati, M., Iannelli, F., Oggioni, M. R., Stefani, S., Pozzi, G. (2000). Characterization of a Genetic Element Carrying the Macrolide Efflux Gene mef(A) in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44: 2585-2587 [Abstract] [Full Text]  
  • Portillo, A., Ruiz-Larrea, F., Zarazaga, M., Alonso, A., Martinez, J. L., Torres, C. (2000). Macrolide Resistance Genes in Enterococcus spp.. Antimicrob. Agents Chemother. 44: 967-971 [Abstract] [Full Text]  
  • Arpin, C., Canron, M.-H., Maugein, J., Quentin, C. (1999). Incidence of mefA and mefE Genes in Viridans Group Streptococci. Antimicrob. Agents Chemother. 43: 2335-2336 [Full Text]  
  • Arpin, C., Canron, M.-H., Noury, P., Quentin, C. (1999). Emergence of mefA and mefE genes in beta-haemolytic streptococci and pneumococci in France. J Antimicrob Chemother 44: 133-134 [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arpin, C.
Right arrow Articles by Quentin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arpin, C.
Right arrow Articles by Quentin, C.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»